LA BioMed: Bringing medical discoveries into the marketplace

Public release date: 11-Jun-2012
[ | E-mail | Share ]

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)

LOS ANGELES (June 11, 2012) The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) is at the forefront of public-private partnerships in order to bring medical discoveries into the marketplace.

KYTHERA Biopharmaceuticals, Inc. is one of several companies founded based on technology licensed from LA BioMed. KYTHERA, which recently filed its registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock, develops prescription products for the aesthetic medicine market, including ATX-101, a potential first-in-class injectable drug candidate being studied for the reduction of submental fat, which leads to the appearance of a so-called "double chin."

"LA BioMed is proud to have a distinguished group of scientists conducting research in many areas that is leading to new therapies and treatments that can benefit thousands of people," said David Meyer, Ph.D., president and CEO of LA BioMed. "From aesthetic properties such as ATX-101, to vaccines for hospital-acquired infections, to sickle cell therapies, our talented researchers are uncovering medical breakthroughs that continue to positively affect individuals in our local communities and around the world."

Michael Kolodney, M.D., Ph.D., lead investigator at LA BioMed and long-time Research Advisor to KYTHERA, is co-inventor of ATX-101. In 2004, he and his colleagues at LA BioMed originally published findings from laboratory observations of fat dissolution using sodium deoxycholate, an endogenous compound that is present in the body to promote the natural breakdown of dietary fat. These findings culminated in the licensing and development of ATX-101 by KYTHERA, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market.

KYTHERA's collaborator, Bayer, has completed pivotal European Phase III trials, and KYTHERA is currently conducting Phase III clinical development in the United States. Phase III clinical trials are large, randomized studies conducted at multiple sites to determine the safety and efficacy of a potential treatment, and are usually the last clinical trials conducted before approval from the Food & Drug Administration (FDA) is obtained and the treatment can be made widely available to the patient population. Currently, there are no FDA-approved pharmacologic therapies for reducing submental fat. As a result, liposuction and surgical neck lifts remain the primary options for patients. KYTHERA and Bayer are developing ATX-101 to address this unmet need.

The relationship of KYTHERA as a small business entity to LA BioMed as an academic research institution is an important one, in that it gives inventors the opportunity to license their technology and bring it from the laboratory into the marketplace in the shortest possible amount of time. The rapid pace with which LA BioMed's physician-researchers are able to take their medical discoveries in the laboratory and apply such discoveries to patients' bedsides has become a staple at the Institution.

###

About KYTHERA Biopharmaceuticals, Inc.

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA's product candidate, ATX-101, is a potential first-in-class, injectable treatment currently in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA also maintains active research interests in hair and fat biology, pigmentation modulation and facial contouring. Find more information at http://www.kytherabiopharma.com.

About LA BioMed

Founded in 1952, LA BioMed is one of the country's leading nonprofit independent biomedical research institutes. It has approximately 100 principal researchers conducting studies into improved treatments and cures for cancer, inherited diseases, infectious diseases, illnesses caused by environmental factors and more. It also educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs. LA BioMed is academically affiliated with the David Geffen School of Medicine at UCLA and located on the campus of Harbor-UCLA Medical Center. For more information, please visit www.LABioMed.org

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Public release date: 11-Jun-2012
[ | E-mail | Share ]

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)

LOS ANGELES (June 11, 2012) The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) is at the forefront of public-private partnerships in order to bring medical discoveries into the marketplace.

KYTHERA Biopharmaceuticals, Inc. is one of several companies founded based on technology licensed from LA BioMed. KYTHERA, which recently filed its registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock, develops prescription products for the aesthetic medicine market, including ATX-101, a potential first-in-class injectable drug candidate being studied for the reduction of submental fat, which leads to the appearance of a so-called "double chin."

"LA BioMed is proud to have a distinguished group of scientists conducting research in many areas that is leading to new therapies and treatments that can benefit thousands of people," said David Meyer, Ph.D., president and CEO of LA BioMed. "From aesthetic properties such as ATX-101, to vaccines for hospital-acquired infections, to sickle cell therapies, our talented researchers are uncovering medical breakthroughs that continue to positively affect individuals in our local communities and around the world."

Michael Kolodney, M.D., Ph.D., lead investigator at LA BioMed and long-time Research Advisor to KYTHERA, is co-inventor of ATX-101. In 2004, he and his colleagues at LA BioMed originally published findings from laboratory observations of fat dissolution using sodium deoxycholate, an endogenous compound that is present in the body to promote the natural breakdown of dietary fat. These findings culminated in the licensing and development of ATX-101 by KYTHERA, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market.

KYTHERA's collaborator, Bayer, has completed pivotal European Phase III trials, and KYTHERA is currently conducting Phase III clinical development in the United States. Phase III clinical trials are large, randomized studies conducted at multiple sites to determine the safety and efficacy of a potential treatment, and are usually the last clinical trials conducted before approval from the Food & Drug Administration (FDA) is obtained and the treatment can be made widely available to the patient population. Currently, there are no FDA-approved pharmacologic therapies for reducing submental fat. As a result, liposuction and surgical neck lifts remain the primary options for patients. KYTHERA and Bayer are developing ATX-101 to address this unmet need.

The relationship of KYTHERA as a small business entity to LA BioMed as an academic research institution is an important one, in that it gives inventors the opportunity to license their technology and bring it from the laboratory into the marketplace in the shortest possible amount of time. The rapid pace with which LA BioMed's physician-researchers are able to take their medical discoveries in the laboratory and apply such discoveries to patients' bedsides has become a staple at the Institution.

###

About KYTHERA Biopharmaceuticals, Inc.

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA's product candidate, ATX-101, is a potential first-in-class, injectable treatment currently in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA also maintains active research interests in hair and fat biology, pigmentation modulation and facial contouring. Find more information at http://www.kytherabiopharma.com.

About LA BioMed

Founded in 1952, LA BioMed is one of the country's leading nonprofit independent biomedical research institutes. It has approximately 100 principal researchers conducting studies into improved treatments and cures for cancer, inherited diseases, infectious diseases, illnesses caused by environmental factors and more. It also educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs. LA BioMed is academically affiliated with the David Geffen School of Medicine at UCLA and located on the campus of Harbor-UCLA Medical Center. For more information, please visit www.LABioMed.org

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

jerry lee lewis cesar chavez winning lotto numbers lottery tickets mega lottery sag aftra mega mill